Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734534 | 0.86 | TRPV1 (0.46) | TRPV1OPRM1MAPT | |
| SCHEMBL2733688 | 0.85 | TRPV1 (0.47) | TRPV1OPRM1MAPT | |
| SCHEMBL4444917 | 0.84 | TRPV1 (0.52) | TRPV1OPRM1LMNAMAPT | |
| SCHEMBL13823670 | 0.83 | TRPV1 (0.49) | TRPV1OPRM1LMNAMAPT | |
| SCHEMBL4446846 | 0.81 | TRPV1 (0.60) | TRPV1OPRM1LMNAMAPT | |
| SCHEMBL4444412 | 0.81 | TRPV1 (0.60) | TRPV1OPRM1LMNAMAPT | |
| SCHEMBL13753755 | 0.81 | TRPV1 (0.54) | TRPV1OPRM1MAPT | |
| SCHEMBL4444559 | 0.80 | TRPV1 (0.59) | TRPV1OPRM1LMNAMAPT | |
| SCHEMBL4441373 | 0.80 | TRPV1 (0.55) | TRPV1OPRM1LMNAMAPT | |
| SCHEMBL4442121 | 0.80 | TRPV1 (0.55) | TRPV1OPRM1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-7381840-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl- group; vanilloid receptor antagonists | XENTION LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-7381840-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl- group; vanilloid receptor antagonists | XENTION LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| EP-1569896-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | OPRL1, OPRK1, VAT1 | TRPV1 5/4885OPRM1 124/4885LMNA 1986/4885 |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | TNNC1, CACNA1H, TNNI3 | TRPV1 13/4885OPRM1 225/4885LMNA 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.